Tsai and colleagues note that even though meds like Wegovy and Zepbound are effective in helping people shed pounds, the drugs' "high cost and high rates of gastrointestinal adverse effects can lead to treatment cessation and subsequent weight regain." Demand for weight-loss meds has also outstripped supply, so it's possible that the number of weight-loss surgery patients may rise again if "ongoing national shortages" of GLP-1s continue, the research team added
Serious, though rare, side effects include pancreatitis and gallbladder issues
A 2024 real-world study of 70,654 adults with type 2 diabetes found that weekly GLP-1 injections had significantly higher adherence than daily options, with an odds ratio of 1.25 (95% CI 1.21-1.28)
Retrieved from Pitkowska-Chmiel, I., Wicha-Komsta, K., Pawowski, K., et al